Using CRISPR/Cas9-Mediated GLA-null Cell Lines as An In Vitro Drug Screening Model for Fabry Disease
碩士 === 國立陽明大學 === 藥理學研究所 === 104 === Fabry disease is a hereditary, X-linked lysosomal storage disease resulting from deficient activity of the lysosomal α-galactosidase A. It leads to progressive accumulation of glycosphingolipids particularly globotriaosylceramide (GL-3) in lysosomes of the heart,...
Main Authors: | Miao-Chia Yang, 楊苗佳 |
---|---|
Other Authors: | Shih-Hwa Chiou |
Format: | Others |
Language: | en_US |
Published: |
2016
|
Online Access: | http://ndltd.ncl.edu.tw/handle/49926843078539991979 |
Similar Items
-
Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease
by: Hui-Yung Song, et al.
Published: (2016-12-01) -
Generating CRISPR-Cas9-Mediated Null Mutations and Screening Targeting Efficiency in Human Pluripotent Stem Cells
by: Alanis-Lobato, G., et al.
Published: (2021) -
Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9
by: Young-Kyu Kim, et al.
Published: (2020-01-01) -
Generation of an in vitro model for peripheral neuropathy in Fabry disease using CRISPR-Cas9 in the nociceptive dorsal root ganglion cell line 50B11
by: Hanover, J.A, et al.
Published: (2022) -
Functional evaluation of a novel GLA causative mutation in Fabry disease
by: Ping Li, et al.
Published: (2019-09-01)